News in brief: Key Neurotech phase III trial underway; London dates confirmed for Cannabis Europa; Vitura sets AGM date by Steve Jones September 22, 2026September 24, 2026 Drug development firm Neurotech International (NTI) has dosed the first patient in its pivotal phase III […]
News in brief: Canopy expands Australian portfolio; Neurotech CEO departs; Elixinol completes US sale by Adam Sheldon September 8, 2026September 9, 2026
Neurotech shares jump 25% as chairman speaks of ‘considerable opportunity’ by Steve Jones August 27, 2026August 27, 2026
News in brief: LGP elects directors; Neurotech appoints Davies as executive chairman by Adam Sheldon August 18, 2026August 18, 2026
Financial news in brief: Avecho CBD trial latest; Argent’s milestone delivery; Neurotech reassures ASX by Steve Jones April 29, 2026June 8, 2026
Autism data hits ‘registration benchmark’ as Neurotech prepares for Phase III clinical trial by Adam Sheldon March 25, 2026March 26, 2026
News in brief: Vitura signs MedReleaf deal; Neurotech initiates first site for Phase 3 autism trial by Adam Sheldon March 17, 2026June 8, 2026
News in brief: Epsilon launches biotech arm; LGP sells WA facility for $7.8m; Neurotech partners with University of Sydney on Rett program by Adam Sheldon February 18, 2026June 8, 2026
Financial news in brief: Avecho; InhaleRx; Neurotech; Peak; Zelira; Argent by Adam Sheldon February 2, 2026June 8, 2026
